These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Frediani B, Cavalieri L, Cremonesi G. Clin Drug Investig; 2009; 29(6):359-79. PubMed ID: 19432497 [Abstract] [Full Text] [Related]
31. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Dunn CJ, Fitton A, Sorkin EM. Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370 [Abstract] [Full Text] [Related]
34. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR. Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877 [Abstract] [Full Text] [Related]
35. No value of oral clodronic acid in malignant osteolysis. Prescrire Int; 1998 Aug; 7(36):104. PubMed ID: 10342946 [Abstract] [Full Text] [Related]
37. Effective parenteral clodronate treatment of a child with severe juvenile idiopathic osteoporosis. Melchior R, Zabel B, Spranger J, Schumacher R. Eur J Pediatr; 2005 Jan; 164(1):22-7. PubMed ID: 15517381 [Abstract] [Full Text] [Related]
38. Use of clodronate in multiple myeloma. Jantunen E, Lahtinen R, Laakso M. Leuk Lymphoma; 1995 Oct; 19(3-4):207-11. PubMed ID: 8535211 [Abstract] [Full Text] [Related]
39. [Pharmacology of clodronate and its mechanism of action on bone resorption]. Fleisch H. Bull Cancer; 1993 Oct; 80(10 Suppl):41-4. PubMed ID: 8081029 [No Abstract] [Full Text] [Related]
40. Rationale for the use of clodronate in osteoporosis. Kanis JA, McCloskey EV, Sirtori P, Khan S, Fern D, Eyres K, Aaron J, Beneton MN. Osteoporos Int; 1993 Oct; 3 Suppl 2():S23-8. PubMed ID: 8481595 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]